Second primary malignancies and myeloma therapy: fad or fact?
作者信息
Usmani Saad Z
出版信息
Oncotarget. 2012 Sep;3(9):915-6. doi: 10.18632/oncotarget.661.
Abstract
The risk adaptive therapy approach within low risk patients may involve limiting post-transplant IMiD exposure in patients who have a higher potential for SPM development. It may well be that we are looking at the tip of the iceberg in the year 2012 and SPMs may emerge as an important long-term sequela with further follow-up.
摘要
相似文献
1
Second primary malignancies and myeloma therapy: fad or fact?
Oncotarget. 2012 Sep;3(9):915-6. doi: 10.18632/oncotarget.661.
2
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.
Leuk Lymphoma. 2017 Mar;58(3):560-568. doi: 10.1080/10428194.2016.1207763. Epub 2016 Jul 18.
3
Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606.
4
B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
BMC Cancer. 2019 Nov 27;19(1):1147. doi: 10.1186/s12885-019-6286-9.
5
The risk of secondary primary malignancies after therapy for multiple myeloma.
Leuk Lymphoma. 2015;56(11):3012-21. doi: 10.3109/10428194.2014.974043.
6
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
Acta Haematol. 2017;137(3):123-131. doi: 10.1159/000455937. Epub 2017 Mar 30.
7
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114.
8
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Bone Marrow Transplant. 2013 Mar;48(3):403-7. doi: 10.1038/bmt.2012.142. Epub 2012 Aug 6.
9
Update on second primary malignancies in multiple myeloma: a focused review.
Leukemia. 2014 Jul;28(7):1423-6. doi: 10.1038/leu.2014.22. Epub 2014 Jan 14.
10
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Blood. 2013 Mar 14;121(11):1982-5. doi: 10.1182/blood-2012-08-448563. Epub 2013 Jan 8.
引用本文的文献
1
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Blood. 2013 Jun 6;121(23):4753-7. doi: 10.1182/blood-2012-11-466961. Epub 2013 Apr 19.
本文引用的文献
1
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Blood. 2012 Aug 23;120(8):1597-600. doi: 10.1182/blood-2012-04-421883. Epub 2012 Jun 6.
2
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.
3
Lenalidomide after stem-cell transplantation for multiple myeloma.
N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083.
4
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704.
5
Therapy-related myeloid malignancies in myeloma.
Mediterr J Hematol Infect Dis. 2011;3(1):e2011047. doi: 10.4084/MJHID.2011.047. Epub 2011 Oct 24.
6
Treatment of multiple myeloma.
Nat Rev Clin Oncol. 2011 Apr 26;8(8):479-91. doi: 10.1038/nrclinonc.2011.63.
7
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2.
8
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Blood. 2008 Jan 1;111(1):94-100. doi: 10.1182/blood-2007-06-097444. Epub 2007 Sep 25.
9
Antitumor activity of thalidomide in refractory multiple myeloma.
N Engl J Med. 1999 Nov 18;341(21):1565-71. doi: 10.1056/NEJM199911183412102.
Zotero 插件